BR112015016282A2 - crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado - Google Patents

crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado

Info

Publication number
BR112015016282A2
BR112015016282A2 BR112015016282A BR112015016282A BR112015016282A2 BR 112015016282 A2 BR112015016282 A2 BR 112015016282A2 BR 112015016282 A BR112015016282 A BR 112015016282A BR 112015016282 A BR112015016282 A BR 112015016282A BR 112015016282 A2 BR112015016282 A2 BR 112015016282A2
Authority
BR
Brazil
Prior art keywords
crenolanib
treatment
proliferative disorders
flt3
mutated
Prior art date
Application number
BR112015016282A
Other languages
English (en)
Inventor
K Jain Vinay
Original Assignee
Arog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51061430&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015016282(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arog Pharmaceuticals Inc filed Critical Arog Pharmaceuticals Inc
Publication of BR112015016282A2 publication Critical patent/BR112015016282A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general

Abstract

resumo “crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado”. a presente invenção refere-se à utilização de crenolanibe, numa forma de sal farmacologicamente aceitável para o tratamento de distúrbios proliferativos de flt3 mutado em consequência de mutantes flt3 constitutivos ativados e a um método de tratamento de animais de sangue quente, preferivelmente humanos, no qual é administrada uma dose de crenolanibe terapeuticamente eficaz a um animal sofrendo da dita doença ou condição.
BR112015016282A 2013-01-07 2013-07-10 crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado BR112015016282A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361749695P 2013-01-07 2013-01-07
PCT/US2013/064821 WO2014107209A2 (en) 2013-01-07 2013-10-14 Crenolanib for treating flt3 mutated proliferative disorders

Publications (1)

Publication Number Publication Date
BR112015016282A2 true BR112015016282A2 (pt) 2017-07-11

Family

ID=51061430

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015016282A BR112015016282A2 (pt) 2013-01-07 2013-07-10 crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado

Country Status (31)

Country Link
US (7) US9101624B2 (pt)
EP (1) EP2941251B1 (pt)
JP (1) JP6288726B2 (pt)
KR (1) KR101885952B1 (pt)
CN (4) CN112138010A (pt)
AP (1) AP2015008628A0 (pt)
AU (1) AU2013371624B2 (pt)
BR (1) BR112015016282A2 (pt)
CA (1) CA2897445C (pt)
CL (1) CL2015001923A1 (pt)
CY (1) CY1120026T1 (pt)
DK (1) DK2941251T3 (pt)
EA (1) EA033910B1 (pt)
ES (1) ES2667958T3 (pt)
HK (1) HK1224211A1 (pt)
HR (1) HRP20180478T1 (pt)
HU (1) HUE038594T2 (pt)
IL (1) IL239802B (pt)
LT (1) LT2941251T (pt)
MX (1) MX369137B (pt)
NO (1) NO3019692T3 (pt)
NZ (1) NZ710720A (pt)
PE (1) PE20151525A1 (pt)
PH (1) PH12015501531B1 (pt)
PL (1) PL2941251T3 (pt)
PT (1) PT2941251T (pt)
RS (1) RS57076B1 (pt)
SG (2) SG11201505327SA (pt)
SI (1) SI2941251T1 (pt)
WO (1) WO2014107209A2 (pt)
ZA (1) ZA201505545B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CA3015753A1 (en) * 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
EP3515559A4 (en) * 2016-09-20 2020-07-15 Dana-Farber Cancer Institute, Inc. COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS
PE20191238A1 (es) * 2016-11-02 2019-09-11 Arog Pharmaceuticals Inc Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
CN114828842A (zh) * 2019-10-21 2022-07-29 理森制药股份公司 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物
US11713310B2 (en) 2020-07-20 2023-08-01 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US20220047574A1 (en) * 2020-08-15 2022-02-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pdgfr alpha mutated proliferative disorders
EP4210847A1 (en) 2020-09-02 2023-07-19 Daniel Choi Systems and methods for augmented reality environments and tokens
JP2023063189A (ja) * 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
JP2001518470A (ja) 1997-09-26 2001-10-16 メルク エンド カムパニー インコーポレーテッド 新規な血管形成阻害剤
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
ES2247187T3 (es) 2000-10-17 2006-03-01 MERCK & CO., INC. Sales oralmente activas conactividad tirosina quinasa.
WO2002036563A1 (en) * 2000-10-31 2002-05-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of fluvastatin sodium
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
PL211461B1 (pl) 2001-10-30 2012-05-31 Dana Farber Cancer Inst Inc Zastosowanie pochodnych staurosporyny do wytwarzania kompozycji farmaceutycznej do leczenia lub zapobiegania białaczkom i zespołom mielodysplastycznym, preparat farmaceutyczny do leczenia białaczek i zestaw farmaceutyczny
CA2470480C (en) 2001-12-27 2010-12-14 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
RU2005106871A (ru) 2002-08-14 2005-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ и их применение
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
JPWO2004039782A1 (ja) 2002-10-29 2006-03-02 麒麟麦酒株式会社 Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
KR20110108404A (ko) 2002-11-13 2011-10-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 암을 치료하는 방법 및 관련 방법
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
WO2004058749A1 (en) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
KR100787649B1 (ko) 2003-06-24 2007-12-21 화이자 프로덕츠 인크. 1-[(벤조이미다졸-1-일)퀴놀린-8-일]피페리딘-4-일아민유도체의 제조 방법
CN101296928B (zh) * 2005-10-28 2011-01-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
WO2013082499A1 (en) * 2011-11-30 2013-06-06 Cedars-Sinai Medical Center Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型ｃ－ｋｉｔ的方法
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado

Also Published As

Publication number Publication date
US20190183879A1 (en) 2019-06-20
US11458131B2 (en) 2022-10-04
MX2015008777A (es) 2015-11-13
CN105555272A (zh) 2016-05-04
KR101885952B1 (ko) 2018-08-06
PH12015501531A1 (en) 2015-09-21
CA2897445C (en) 2019-04-30
HRP20180478T1 (hr) 2018-06-15
US20180015081A1 (en) 2018-01-18
WO2014107209A2 (en) 2014-07-10
CN110200970A (zh) 2019-09-06
EP2941251B1 (en) 2018-03-07
CL2015001923A1 (es) 2016-01-15
IL239802B (en) 2020-06-30
US10213423B2 (en) 2019-02-26
SI2941251T1 (en) 2018-06-29
MX369137B (es) 2019-10-30
NZ710720A (en) 2020-06-26
US9801870B2 (en) 2017-10-31
ES2667958T3 (es) 2018-05-16
RS57076B1 (sr) 2018-06-29
PH12015501531B1 (en) 2015-09-21
EP2941251A2 (en) 2015-11-11
SG10201705611PA (en) 2017-08-30
AP2015008628A0 (en) 2015-08-31
EA201591290A3 (ru) 2016-07-29
HUE038594T2 (hu) 2018-10-29
CA2897445A1 (en) 2014-07-10
EA033910B1 (ru) 2019-12-09
CY1120026T1 (el) 2018-12-12
US20160303109A1 (en) 2016-10-20
US20140194464A1 (en) 2014-07-10
DK2941251T3 (en) 2018-03-26
EP2941251A4 (en) 2016-08-24
HK1224211A1 (zh) 2017-08-18
US20200390756A1 (en) 2020-12-17
US11007188B2 (en) 2021-05-18
US9393240B2 (en) 2016-07-19
LT2941251T (lt) 2018-04-10
US20150238479A1 (en) 2015-08-27
US20220409610A1 (en) 2022-12-29
US9101624B2 (en) 2015-08-11
IL239802A0 (en) 2015-08-31
AU2013371624A1 (en) 2015-08-20
PE20151525A1 (es) 2015-10-23
SG11201505327SA (en) 2015-08-28
NO3019692T3 (pt) 2018-06-16
PT2941251T (pt) 2018-03-23
AU2013371624B2 (en) 2018-02-08
KR20150141930A (ko) 2015-12-21
PL2941251T3 (pl) 2018-07-31
CN112138010A (zh) 2020-12-29
JP2016508148A (ja) 2016-03-17
JP6288726B2 (ja) 2018-03-07
ZA201505545B (en) 2016-10-26
EA201591290A2 (ru) 2016-03-31
CN109966292A (zh) 2019-07-05

Similar Documents

Publication Publication Date Title
BR112015016282A2 (pt) crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
BR112017008093A2 (pt) processos para tratamento de doenças oculares
CY1123460T1 (el) Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης
BR112017023233A2 (pt) métodos para tratamento de câncer
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
MX2021000538A (es) Uso de sobetirome en el tratamiento de enfermedades de mielinizacion.
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112017010440A2 (pt) administração sublingual de riluzol
CL2017002242A1 (es) Método para tratar un tumor cerebral
BR112019008762A2 (pt) método para o tratamento de um distúrbio proliferativo mutado em flt3
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112017010423A2 (pt) formulação sublingual de riluzol
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
BR112016020260A8 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
BR112017017729A2 (pt) forma de dosagem oral de liberação controlada de agonista de receptor gaba
BR112019005985A2 (pt) composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
JP2016519107A5 (pt)

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law
B12C Appeal against dismissal [chapter 12.3 patent gazette]
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements